Research / Stocks / XRAY XRAY Nasdaq CIK 0000818479
DENTSPLY SIRONA Inc. · Dental Equipment & Supplies
COVERAGE / STANDARD
Latest filing 4 · Aug 12, 2026
Research state Latest filing analysis is current
Last SEC check Sep 13, 2026
Data basis Official SEC · no quote feed Component status Filing Evidence Research Current Official SEC filing history is available
Structured Financials Research Current Validated structured financial research is available
Filing Analysis Research Current No filing analysis job is currently running
Fundamental State Research Current Fundamental State depends on validated comparable financial metrics
RESEARCH SNAPSHOT DENTSPLY SIRONA Inc.'s latest supported as-filed period reports revenue of $898.0M ; gross margin moved 255 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
Deterministic / evidence backed Key research observations No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Current configuration / point in time Fundamental state A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Capex intensity RAW Current state valid · history insufficient
Method Level · gp.fundamentals.capex_revenue_ratio
Raw value 4.90% · OPTIONAL
Operating cash generation RAW Current state valid · history insufficient
Method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 11.02% · OPTIONAL
Revenue growth RAW Current state valid · history insufficient
Method Yoy · gp.fundamentals.revenue
Raw value -4.06% · CORE
Inventory pressure RAW Current state valid · history insufficient
Method Level · gp.fundamentals.inventory_revenue_ratio
Raw value 74.05% · OPTIONAL
Gross margin RAW Current state valid · history insufficient
Method Level · gp.fundamentals.gross_margin
Raw value 54.90% · CORE
Operating margin RAW Current state valid · history insufficient
Method Level · gp.fundamentals.operating_margin
Raw value 9.13% · CORE
R&D intensity RAW Current state valid · history insufficient
Deterministic multi-period research Company direction Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
As filed Jun 30, 2026 General Corporate
Governance Evidence 4 evidence-backed dimensions Filing Amendments Observed Auditor Changes None Detected Sbc Intensity Observed Insider Activity Observed [email protected] · 5 historical states · 50% confidenceInterpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Comparable evidence Peer context Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
Growth
XRAY -4.1
Peer median 9.5
Peer percentile 20th 181 valid peers · 91% coverage · -0.8 robust σ Capex Intensity
XRAY 4.9
Peer median 2.9
Peer percentile 77th 168 valid peers · 84% coverage · +0.7 robust σ Sbc Intensity
XRAY 1.0
Peer median 3.8
Peer percentile 13th 183 valid peers · 92% coverage · -0.7 robust σ R And D Intensity
XRAY 5.0
Peer median 13.5
Peer percentile 21th 151 valid peers · 76% coverage · -0.6 robust σ Profitability
XRAY 9.1
Peer median -3.1
Peer percentile 66th 189 valid peers · 95% coverage · +0.4 robust σ Cash Generation
XRAY 11.0
Peer median 1.4
Peer percentile 65th 186 valid peers · 93% coverage · +0.3 robust σ Open group breadth → Divergence is context, not positive or negative. INSIDER STATE / 90D Recent disclosed activity
Open-market purchases 0
Sales 0
Distinct buyers 0
Repeat buyer NO Conservative Form 4 classification · not a sentiment label Flagship analysis / V3 What changed? The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q 0000818479-26-000255 11 governed changes · top 7 shown
01
HIGH IMPORTANCE Cash 100TH HISTORICAL PCTL · N=2
Cash & equivalents decreased 33.4% Cash & equivalents changed -33.4% from the comparable as-filed period.
Why this ranks here · [email protected] $359.0M → $239.0M Comparable → current
02
MEDIUM IMPORTANCE Margin 67TH HISTORICAL PCTL · N=3
Gross margin moved 255 bp higher Gross margin changed +255 basis points from the comparable as-filed period.
Why this ranks here · [email protected] 52.35% → 54.90% Comparable → current
03
INFORMATIONAL IMPORTANCE Margin 0TH HISTORICAL PCTL · N=3
Gross profit increased 0.6% Gross profit changed +0.6% from the comparable as-filed period.
Why this ranks here · [email protected] $490.0M → $493.0M Comparable → current
04
INFORMATIONAL IMPORTANCE Inventory 0TH HISTORICAL PCTL · N=4
Inventory decreased 1.5% Inventory changed -1.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
As-filed financials Financial trajectory Each point keeps the date investors could first observe it and its accession.
As filed Current normalized · later
Capex / revenue 4.90% -17.1% ↓ Capital expenditure $44.0M -15.4% ↓ Cash & equivalents $239.0M +0.0% ↑ Debt $2.3B +1678.1% ↑ Free-cash-flow proxy $55.0M +558.3% ↑ Gross margin 54.90% +0.0% ↑ Interest expense $18.0M -77.8% ↓ Interest income -$60.0M +0.0% ↑
ACTIVE TRACE Revenue XRAY · as filed with the SEC · reported-date aware
Capex / revenue Q2 / 2026-06-30 4.90% -17.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Capital expenditure Q2 / 2026-06-30 $44.0M -15.4% sequential point Trace ↗ Evidence inspector
Loading lineage… × Cash & equivalents Q2 / 2026-06-30 $239.0M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Debt FY / 2025-12-31 $2.3B +1678.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Free-cash-flow proxy Q2 / 2026-06-30 $55.0M +558.3% sequential point Trace ↗ Evidence inspector
Loading lineage… × Gross margin Q2 / 2026-06-30 54.90% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest expense Q1 / 2024-03-31 $18.0M -77.8% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest income FY / 2022-12-31 -$60.0M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Inventory Q2 / 2026-06-30 $665.0M +0.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Net income Q2 / 2026-06-30 $37.0M +470.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating cash flow Q2 / 2026-06-30 $99.0M +147.5% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating margin Q2 / 2026-06-30 9.13% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Primary evidence Filing timeline Direct SEC links, filing dates, report periods, and amendment flags.
4 Aug 12, 2026 Period Aug 10, 2026 0000818479-26-000268SEC ↗ 4 Aug 11, 2026 Period Aug 7, 2026 0000818479-26-000266SEC ↗ 8-K/A Aug 7, 2026 Period Aug 6, 2026 0000818479-26-000263SEC ↗ 10-Q Aug 6, 2026 Period Jun 30, 2026 0000818479-26-000255SEC ↗ 8-K Aug 6, 2026 Period Aug 6, 2026 0000818479-26-000253SEC ↗ 4 Jul 1, 2026 Period Jun 30, 2026 0000818479-26-000234SEC ↗ 4/A Jun 18, 2026 Period Jun 12, 2026 0000818479-26-000218SEC ↗ Form 4 Insider activity Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
“Insider purchase” rule Code P · non-derivative · acquired · direct ownership · positive price and shares · not amended
Inspectable by design
Every displayed number has a lineage. GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗